Elemental Enzymes Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$61K
- Investors
-
6
Elemental Enzymes General Information
Description
Developer of organic enzymes intended to develop novel solutions for complex problems in commercial agriculture and research and development. The company's enzymes use newly patented technologies and the latest scientific advancements to assist customers in getting biological products, stabilized enzymes, proteins, peptides and specialty chemicals that can address key market needs, enabling customers to overcome their environmental challenges or create new market opportunities.
Contact Information
Website
www.elementalenzymes.com
Formerly Known As
Spogen Biotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Agricultural Chemicals
Other Industries
Specialty Chemicals
Biotechnology
Primary Office
- 1685 Galt Industrial Boulevard
- Saint Louis, MO 63132
- United States
+1 (314) 000-0000
Elemental Enzymes Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 22-Dec-2020 | $61K | 00000 | Completed | Generating Revenue | |
| 5. Early Stage VC | 01-Dec-2016 | 0000 | 00000 | Completed | Generating Revenue | |
| 4. Secondary Transaction - Private | 00000 | 00000 | Completed | Startup | ||
| 3. Angel (individual) | 0000 | 00000 | Completed | Startup | ||
| 2. Seed Round | 01-Jan-2013 | $300K | $470K | Completed | Startup | |
| 1. Seed Round | $170K | $170K | Completed | Startup |
Elemental Enzymes Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elemental Enzymes Patents
Elemental Enzymes Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020241393-A1 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | Pending | 19-Mar-2019 | 0000000000 | |
| CA-3133987-A1 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | Pending | 19-Mar-2019 | 0000000000 | |
| EP-3941931-A1 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | Pending | 19-Mar-2019 | 0000000000 | |
| US-20220169999-A1 | Fusion proteins, recombinant bacteria, and exosporium fragements for plant health | Pending | 19-Mar-2019 | 0000000000 | |
| AU-2020210909-A1 | Compositions for treating citrus disease and promoting yield increase in row crops | Pending | 23-Jan-2019 | C12N9/2442 |
Elemental Enzymes Executive Team (8)
Elemental Enzymes Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Elemental Enzymes Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CRDF Global | Corporation | 000 0000 | 000000 0 | ||
| Allen Angel Capital | University | Minority | 000 0000 | 000000 0 | |
| Centennial Investors | Angel Group | Minority | 000 0000 | 000000 0 | |
| St. Louis Arch Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| Brent Beshore | Angel (individual) | Minority | 000 0000 | 000000 0 |